Development of an Intelligent Reactive Oxygen Species-Responsive Dual-Drug Delivery Nanoplatform for Enhanced Precise Therapy of Acute Lung Injury
Dunling Xia,Zongqing Lu,Shuai Li,Pu Fang,Chun Yang,Xiaoyan He,Qinghai You,Gengyun Sun
DOI: https://doi.org/10.2147/ijn.s442727
IF: 7.033
2024-03-06
International Journal of Nanomedicine
Abstract:Dunling Xia, 1 Zongqing Lu, 1 Shuai Li, 1 Pu Fang, 1 Chun Yang, 2 Xiaoyan He, 3 Qinghai You, 1 Gengyun Sun 1 1 Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China; 2 Department of Emergency Intensive Care Unit, the First Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China; 3 School of Life Sciences, Anhui Medical University, Hefei, People's Republic of China Correspondence: Qinghai You; Gengyun Sun, Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Anhui Medical University, 218 Jixi Road, Sanli'an Street, Shushan District, Hefei, Anhui Province, 230032, People's Republic of China, Tel +86 551 6292 2913, Fax +86 551 6292 2752, Email ; Introduction: Acute lung injury (ALI) and its most severe form acute respiratory distress syndrome (ARDS) are commonly occurring devastating conditions that seriously threaten the respiratory system in critically ill patients. The current treatments improve oxygenation in patients with ALI/ARDS in the short term, but do not relieve the clinical mortality of patients with ARDS. Purpose: To develop the novel drug delivery systems that can enhance the therapeutic efficacy of ALI/ARDS and impede adverse effects of drugs. Methods: Based on the key pathophysiological process of ARDS that is the disruption of the pulmonary endothelial barrier, bilirubin (Br) and atorvastatin (As) were encapsulated into an intelligent reactive oxygen species (ROS)-responsive nanocarrier DSPE-TK-PEG (DPTP) to form nanoparticles (BA@DPTP) in which the thioketal bonds could be triggered by high ROS levels in the ALI tissues. Results: BA@DPTP could accumulate in inflammatory pulmonary sites through passive targeting strategy and intelligently release Br and As only in the inflammatory tissue via ROS-responsive bond, thereby enhancing the drugs effectiveness and markedly reducing side effects. BA@DPTP effectively inhibited NF-κB signaling and NLRP3/caspase-1/GSDMD-dependent pyroptosis in mouse pulmonary microvascular endothelial cells. BA@DPTP not only protected mice with lipopolysaccharide-induced ALI and retained the integrity of the pulmonary structure, but also reduced ALI-related mortality. Conclusion: This study combined existing drugs with nano-targeting strategies to develop a novel drug-targeting platform for the efficient treatment of ALI/ARDS. Keywords: acute lung injury, acute respiratory distress syndrome, reactive oxygen species-responsiveness, nanoparticles, bilirubin, atorvastatin Both acute lung injury (ALI) and the more severe form acute respiratory distress syndrome (ARDS) are serious illnesses that commonly affect the respiratory system of critically ill patients. 1 The mortality rate of patients with severe ARDS is as high as 45%, which places a tremendous burden on the global healthcare system. 2,3 History has repeatedly shown that pathogens can cause catastrophic damage to the human respiratory system. Many respiratory viruses could cause severe runaway immune-mediated ROS damage, such as Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome can cause ALI/ARDS. 4,5 The severe acute respiratory syndrome coronavirus 2, responsible for the recent Coronavirus disease 2019 (COVID-19) pandemic, is also an example. According to the report by the World Health Organization, the current confirmed global COVID-19-related deaths due to acute respiratory failure have exceeded 7 million. 6,7 Because of the unique physiological barriers of the lung, pulmonary drug delivery to inflamed tissues is relatively inefficient, resulting in decreased drug therapeutic effectiveness and enhanced systemic side effects. 8 Therefore, the development of novel drug delivery systems that can enhance the therapeutic efficacy and impede adverse effects of drugs is urgent for successful ALI/ARDS therapy. The most common inducement for ALI/ARDS is lung infection. A key underlying pathogenic mechanism is the breakdown of the lung endothelial barrier function due to widespread endothelial cell death and disassembly of endothelial adherens junctions, which can lead to protein-rich non-hydrostatic pulmonary edema, lung stiffness, reduced lung volume, refractory hypoxemia and impairment of lung function in eliminating carbon dioxide. 9–11 The endothelium is distributed throughout the entire vascular system, especially the lung endothelium, which accounts for approximately 50% of all lung cells and receives the total right cardiac output. 12 The complete endothelial -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology